Geron (NASDAQ:GERN) Posts Earnings Results, Hits Expectations

Geron (NASDAQ:GERN) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.04), Zacks reports. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%.

Geron Trading Down 29.8 %

Shares of NASDAQ GERN traded down $0.71 during trading on Wednesday, hitting $1.66. 69,018,225 shares of the company were exchanged, compared to its average volume of 13,535,564. Geron has a 12-month low of $1.46 and a 12-month high of $5.34. The firm has a market capitalization of $1.01 billion, a PE ratio of -5.14 and a beta of 0.53. The company has a fifty day moving average price of $3.05 and a 200-day moving average price of $3.83. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Analyst Ratings Changes

GERN has been the subject of several research reports. Barclays raised Geron to a “strong-buy” rating in a report on Friday, November 29th. B. Riley cut their price target on shares of Geron from $5.50 to $3.50 and set a “buy” rating for the company in a report on Tuesday, February 18th. Needham & Company LLC upped their price objective on shares of Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Finally, HC Wainwright lowered Geron from a “buy” rating to a “neutral” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $6.91.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.